-
Security Type
-
Revenue Sharing
-
Categories
-
Health & Fitness
-
Min Investment
-
$100
-
Offering Date
-
August 30, 2021
-
Expected Close Date
-
October 29, 2021
-
Target Raise
-
$75.00K-$107.00K
-
Security Price
-
$1
Company Description
South Shore Biotherapy’s mission is to improve our client’s quality of life through intravenous infusion therapy and provide hope for a brighter future, free of depression and thoughts of suicide.
Key Deal Facts
Our objective is to bring a proven and effective treatment for depression and thoughts of suicide to the South Shore in the form of ketamine infusion therapy. Infusion therapy effectively alleviates symptoms of depression and thoughts of suicide in approximately 75% of the patient population compared to roughly 40% on traditional depression medications. In some cases, this treatment protocol can even reduce or completely halt suicidal ideation within minutes of treatment.
At South Shore Biotherapy we are determined to become the unmatched provider of ketamine infusion therapy on the South Shore and partner with all our clients in hope to create a life worth living, free of depression.
Management Team / Advisory Board Bios
Adam Joseph Baiardi, Owner
Adam Baiardi is a seasoned healthcare director and owner/operator of South Shore Biotherapy, a startup biotherapy company that provides lifesaving treatment to people with treatment resistant depression or thoughts of suicide. Adam graduated from the New England Institute of Technology with an associate’s degree in Science /Physical Therapy. After graduating and accepting his first full time treating position he quickly found his passion for providing quality patient care but also wanted more control over the financial and operational direction of the department.